Effects of oxycodone pharmacogenetics on postoperative analgesia and related clinical outcomes in children: a pilot prospective study

Pharmacogenomics. 2023 Mar;24(4):187-197. doi: 10.2217/pgs-2022-0149. Epub 2023 Mar 22.

Abstract

Background: Variability in the pharmacokinetics and pharmacodynamics of oxycodone in children undergoing surgery could be due to genetic polymorphisms. Materials & methods: The authors studied the association between clinical outcomes and pharmacogenes in children undergoing major surgery. A total of 89 children (35 undergoing pectus excavatum repair and 54 undergoing spinal fusion) were recruited. Results: OPRM1 SNP rs6902403 showed an association with maximum pain score and total morphine equivalent dose (p < 0.05). Other polymorphisms in OPRM1 SNP, PXR, COMT and ABCB1 were also shown to be associated with average morphine equivalent dose, length of hospital stay and maximum surgical pain (p < 0.05). Conclusion: This study demonstrates novel associations between the above pharmacogenes and oxycodone's pharmacokinetics as well as postoperative outcomes in children. Clinical trial registration: NCT03495388 (ClinicalTrials.gov).

Keywords: ABCB1; COMT; CYP2D6; CYP3A4; OPRM1; PXR; analgesia; children; hospital stay; oxycodone; pharmacogenetics; pharmacokinetics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesia*
  • Analgesics, Opioid / adverse effects
  • Child
  • Humans
  • Morphine / therapeutic use
  • Oxycodone* / adverse effects
  • Pain, Postoperative / drug therapy
  • Pain, Postoperative / genetics
  • Pharmacogenetics
  • Prospective Studies

Substances

  • Oxycodone
  • Analgesics, Opioid
  • Morphine

Associated data

  • ClinicalTrials.gov/NCT03495388